Sionna Therapeutics' (SION) "Neutral" Rating Reiterated at Wedbush

Key Points

• Wedbush reiterated its “Neutral” rating on Sionna Therapeutics and set a $5.00 price target, implying 23.3% upside from the prior close. Analysts overall assign the stock a consensus “Hold” rating with an average target of $42.22.
• Sionna shares fell $46.98 to $4.05 in Monday trading, near the company’s 12-month low of $4.01, amid volume far above average. Sionna also reported a quarterly loss of $0.66 per share, missing expectations by $0.02.
• Insiders have sold 403,726 shares worth approximately $18.3 million over the past three months, including director sales conducted under pre-arranged Rule 10b5-1 plans. Corporate insiders currently own 5.1% of the company.

Sionna Therapeutics (NASDAQ:SION - Get Free Report)'s stock had its "neutral" rating reiterated by Wedbush in a note issued to investors on Monday, MarketBeat.com reports. They presently have a $5.00 price target on the stock. Wedbush's target price would indicate a potential upside of 23.30% from the stock's previous close.

SION has been the subject of a number of other reports. Freedom Capital downgraded shares of Sionna Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 20th. Stifel Nicolaus reissued a "hold" rating and set a $7.00 price objective on shares of Sionna Therapeutics in a research note on Monday. Wall Street Zen downgraded Sionna Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, May 16th. BTIG Research reaffirmed a "buy" rating and issued a $58.00 target price on shares of Sionna Therapeutics in a research report on Wednesday, May 13th. Finally, Raymond James Financial reissued a "strong-buy" rating and set a $59.00 price target on shares of Sionna Therapeutics in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $42.22.

Sionna Therapeutics Stock Performance

NASDAQ SION traded down $46.98 during trading hours on Monday, hitting $4.05. 23,315,454 shares of the company's stock were exchanged, compared to its average volume of 548,288. The business's 50 day moving average is $42.35 and its 200-day moving average is $40.42. Sionna Therapeutics has a 12-month low of $4.01 and a 12-month high of $54.97. The firm has a market capitalization of $183.33 million, a P/E ratio of -1.88 and a beta of 1.32.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.02). As a group, equities research analysts anticipate that Sionna Therapeutics will post -2.63 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Peter A. Thompson sold 115,844 shares of the firm's stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $45.50, for a total transaction of $5,270,902.00. Following the completion of the sale, the director directly owned 2,555,877 shares in the company, valued at $116,292,403.50. This trade represents a 4.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 115,844 shares of the business's stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $45.50, for a total value of $5,270,902.00. Following the completion of the transaction, the director owned 2,555,877 shares in the company, valued at approximately $116,292,403.50. This trade represents a 4.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 403,726 shares of company stock worth $18,259,354. Corporate insiders own 5.10% of the company's stock.

Hedge Funds Weigh In On Sionna Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. State of Wyoming acquired a new stake in Sionna Therapeutics in the second quarter valued at $35,000. GF Fund Management CO. LTD. acquired a new position in Sionna Therapeutics during the 4th quarter worth $36,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Sionna Therapeutics in the 2nd quarter worth about $44,000. Russell Investments Group Ltd. acquired a new stake in shares of Sionna Therapeutics in the 3rd quarter valued at about $30,000. Finally, Balyasny Asset Management L.P. bought a new position in shares of Sionna Therapeutics during the fourth quarter worth about $58,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source